Hypoxia In Cancer Therapy

At ManTRa Diagnostics we have delivered a major advance in personalised cancer medicine, focused on hypoxia in cancer therapy

Through our work, we have found that solid tumours have different amounts of oxygen and low levels (hypoxia) that are associated with resistance to treatment as well as a poor prognosis. In fact, it’s been shown that patients with the most hypoxic tumours have the worst prognosis and the cancer is more likely to spread.

It also shows us that the most hypoxic tumours are more likely to recur following surgery, and hypoxia can be resistant to radiotherapy, chemotherapy and immunotherapy.

Currently, there is currently no way to measure the level of hypoxia in tumours in routine clinical practice

We provide tumour-site-specific gene expression signatures to assess hypoxia. This will allow us to deliver personalised cancer medicine that is more likely to work for patients, thus preventing unnecessary treatments and giving them a better quality of life during treatment.

If you are interested in finding our more about our technology, please register your interest or send us an enquiry through the contact form.

To learn more about our work, you can learn more about us and meet the team, as well as our history and our story.